Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs).

被引：0

作者：

Dasari, Arvind

Li, Daneng

Sung, Max W.

Tucci, Christopher

Kauh, John S.

Kania, Marek K.

Paulson, Andrew Scott

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] City Hope Comprehens Canc Ctr, Dept Med Oncol, Duarte, CA USA

[3] Beckman Res Inst, Duarte, CA USA

[4] Tisch Canc Inst Mt Sinai, New York, NY USA

[5] Hutchison MediPharma, Florham Pk, NJ USA

[6] Eli Lilly & Co, Bridgewater, NJ USA

[7] Hutchison MediPharma Int Inc, Florham Pk, NJ USA

[8] Texas Oncol US Oncol Network, Dallas, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4610

引用

页数：2

共 50 条

[41] Efficacy and safety of surufatinib in unresectable or metastatic grade 3 pancreatic neuroendocrine tumors (NET G3): Real-world analysis.
Wang, Jian
Liang, Yun
Long, Jiang
Chi, Yihebali
Zhang, Suzhen
Wu, Yinying
Wang, Yu
Bai, Chunmei
Hu, Weiyu
Hu, Hanguang
Zhang, Lin
Chen, Jie
Hao, Jing
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 657 - 657
[42] Efficace of long-acting somatostatin analogues (SA) in patients (pts) with highly differentiated gastroenteropancreatic neuroendocrine tumors (GEP NETs)
Markovich, Alla
Nadezhda, Orel
Armen, Margaryan
Alexander, Kuzminov
Galina, Emelyanova
Anastasia, Odintsova
Vera, Gorbunova
ANNALS OF ONCOLOGY, 2017, 28
[43] TREATMENT PATTERNS AND HEALTH CARE RESOURCE UTILIZATION OF PATIENTS WITH NEUROENDOCRINE TUMORS IN THE UNITED STATES
Chuang, C. C.
Dinet, J.
Bhurke, S.
Chen, S. Y.
Bnilais, S.
Gabriel, S.
VALUE IN HEALTH, 2014, 17 (03) : A137 - A138
[44] Survival trend among patients with advanced pancreatic neuroendocrine tumors in United States.
Kunwor, Ranju
Ghimire, Krishna Bilas
Nepal, Mahesh
Baniya, RamKaji
Ho, Dominic
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[45] PAZONET: A PHASE II TRIAL OF PAZOPANIB AS A SEQUENCING TREATMENT IN PROGRESSIVE METASTATIC NEUROENDOCRINE TUMORS (NETS) PATIENTS (PTS), ON BEHALF OF THE SPANISH TASK FORCE FOR NETS (GETNE)
Grande, E.
Castellano, D.
Garcia-Carbonero, R.
Teule, A.
Duran, I.
Fuster, J.
Sevilla, I.
Escudero, P.
Sastre, J.
Casanovas, O.
Ortega, L.
Earl, J.
Diez, J. J.
de Velasco, G.
Longo, F.
Navarro, A.
Pachon, V.
Carrato, A.
Salazar, R.
Capdevila, J.
ANNALS OF ONCOLOGY, 2012, 23 : 377 - 377
[46] The Efficacy and Safety of Sunitinib in Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 10 - 11
[47] The Efficacy and Safety of Sunitinib in Patients With Advanced Well-differentiated Pancreatic Neuroendocrine Tumors
Raymond, Eric
Kulke, Matthew
Qin, Shukui
Schenker, Michael
Cubillo, Antonio
Lou, Wenhui
Tomasek, Jiri
Thiis-Evensen, Espen
Xu, Jianming
Racz, Karoly
Croitoru, Adina
Khasraw, Mustafa
Sedlackova, Eva
Borbath, Ivan
Ruff, Paul
Oberstein, Paul
Ito, Tetsuhide
Fernandez, Kathrine
Rosbrook, Brad
Fazio, Nicola
PANCREAS, 2017, 46 (03) : 435 - 435
[48] US real-world study of the burden of medication in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Chan, J. A.
Houchard, A.
Pommie, C.
Ribeiro-Oliveira, A., Jr.
Starr, J.
Vandamme, T.
JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 86 - 86
[49] Safety and Efficacy of the S-1/Temozolomide Regimen in Patients with Metastatic Neuroendocrine Tumors
Zhao, Jiuda
Zhao, Hong
Chi, Yihebali
NEUROENDOCRINOLOGY, 2018, 106 (04) : 318 - 323
[50] Safety and efficacy of combination of temozolomide and pazopanib in patients with advanced pancreatic neuroendocrine tumors (PNET).
Nimeiri, Halla Sayed
Pai, Sachin Gopalkrishn
Chiorean, E. Gabriela
Rademaker, Alfred
Kircher, Sheetal Mehta
Mulcahy, Mary Frances
Cohen, Steven J.
Denlinger, Crystal Shereen
Sahai, Vaibhav
Zalupski, Mark
Berlin, Jordan
Benson, Al Bowen
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 4 5 →